eduKate SG

Three learners review open books together at a classroom table, with stacks of textbooks, stationery and a whiteboard in the bright room.

The Immune Thrombotic Thrombocytopenic Purpura Web | From Platelet Fall and Microangiopathic Haemolysis to ADAMTS13, Plasma Exchange, Caplacizumab and Remission

Quick Read

Immune TTP is not simply “low platelets plus haemolysis”. It is a life-threatening thrombotic microangiopathy driven by severe ADAMTS13 deficiency, usually from autoantibodies, leading to platelet-rich microthrombi that can injure brain, heart, kidneys and other organs.

The distinct Medicine Web job is: thrombocytopenia + microangiopathic haemolytic anaemia ± neurological/cardiac/renal signs → estimate TTP probability → draw ADAMTS13 sample before plasma therapy if feasible → do not delay urgent treatment in high-probability disease → therapeutic plasma exchange + corticosteroid pathway → caplacizumab and rituximab according to specialist strategy → daily platelet/haemolysis/organ receipt → ADAMTS13-guided remission surveillance → relapse prevention.

Wait, What? The Most Important Test May Return After Treatment Has Already Started

Current ISTH guidance recommends obtaining ADAMTS13 activity before plasma exchange or blood products when possible, but starting plasma exchange and corticosteroids without waiting for the result when clinical suspicion is high. Caplacizumab can also be considered early in the appropriate setting.

Anti-collapse rules: thrombocytopenia ≠ TTP; schistocytes ≠ TTP automatically; normal PT/aPTT ≠ benign disease; ADAMTS13 pending ≠ treatment should wait in high-probability TTP; platelet recovery ≠ immune remission guaranteed; discharge ≠ relapse risk gone.

The iTTP Tube

Platelet fall + haemolysis signal → smear/LDH/haptoglobin/reticulocyte/renal/neuro/cardiac evidence → pre-test probability → ADAMTS13 sample → urgent TPE + corticosteroid strategy → caplacizumab/rituximab as appropriate → daily platelet and organ response → stop acute therapy when remission criteria are met → ADAMTS13 surveillance → relapse-prevention route.

1. The Owner Is ADAMTS13-Deficient Microvascular Thrombosis

DIC owns systemic coagulation activation; HIT owns heparin-triggered platelet activation. TTP owns severe ADAMTS13 deficiency causing platelet-rich microvascular thrombosis with microangiopathic haemolysis.

2. The Blood Film Shows Mechanical Red-Cell Injury

Schistocytes, raised LDH, reduced haptoglobin and reticulocytosis can support microangiopathic haemolysis. The pattern helps identify thrombotic microangiopathy but is not unique to TTP.

3. Platelet Count Is a Disease-Activity Receipt

Severe thrombocytopenia is common and platelet recovery is an important treatment response, but organ injury and ADAMTS13 activity remain separate objects.

4. Neurological Symptoms Can Fluctuate

Headache, confusion, focal deficits, seizures or reduced consciousness may occur as microthrombi affect cerebral circulation. A normal scan does not exclude microvascular disease.

5. Cardiac Injury Can Be Hidden

Troponin elevation, arrhythmia or heart failure can occur from myocardial microvascular injury. Cardiac monitoring therefore belongs in severe presentations.

6. Plasma Exchange Replaces What Is Missing and Removes What Is Harmful

Therapeutic plasma exchange both supplies functional ADAMTS13 and removes circulating autoantibodies and other plasma factors. It remains a core emergency treatment in immune TTP.

7. Corticosteroids Target the Autoimmune Driver

Immunosuppression reduces ongoing autoantibody production. Rituximab may be added in acute treatment or relapse-prevention strategies depending on disease course and specialist judgment.

8. Caplacizumab Targets Platelet–von Willebrand Factor Interaction

Caplacizumab can reduce ongoing microvascular platelet adhesion while the autoimmune process is brought under control. It changes thrombotic activity quickly but does not eliminate the underlying anti-ADAMTS13 autoimmunity by itself.

9. ADAMTS13 Is a Diagnostic and Long-Term Monitoring Object

Severe deficiency strongly supports TTP. During remission, persistently or recurrently low ADAMTS13 can identify relapse risk and inform pre-emptive immunosuppressive strategies.

10. TTP and DIC Must Stay Separate

The DIC Web owns consumption coagulopathy driven by systemic coagulation activation. TTP usually has a different coagulation profile and a fundamentally different treatment system.

11. Platelet Transfusion Is Not a Routine Reflex

Because platelet-rich microthrombi are central to TTP pathophysiology, platelet transfusion is generally reserved for compelling bleeding or procedural indications rather than used simply because the count is low.

12. Remission Is More Than a Normal Platelet Count

Clinical remission includes sustained platelet recovery and resolution of haemolysis/organ injury. Immunological remission and ADAMTS13 recovery may lag behind.

13. Relapse Is a Longitudinal Disease State

Patients can relapse months or years later. Education about symptoms, rapid access to haematology and periodic ADAMTS13 monitoring can reduce delay in future episodes.

14. Evidence, Uncertainty and Correction

ISTH’s 2025 focused update kept the core immune-TTP recommendations unchanged while updating congenital TTP guidance. The correction loop is TMA signal → high/low TTP probability → ADAMTS13 sample → urgent treatment when high probability → platelet/haemolysis/organ receipt → ADAMTS13 result → refine diagnosis and therapy → remission surveillance.

15. RFE: Did We Stop Microvascular Thrombosis Before the Brain, Heart or Kidneys Paid the Price?

The Medicine RFE asks whether timely, evidence-grounded and ethically authorised help reaches the human and improves outcomes without preventable harm. In iTTP, success means treatment was not delayed for laboratory certainty, microvascular thrombosis stopped, organ injury was followed, immune disease was suppressed and relapse risk remained visible after discharge.

eduKateAI iTTP Tube Card

Canonical External Source

International Society on Thrombosis and Haemostasis — TTP Guidelines and 2025 Focused Update

Educational boundary: Suspected TTP is a haematological emergency. This page explains information architecture and does not prescribe plasma exchange, corticosteroids, caplacizumab or rituximab for an individual.

Explore the connected learning guides

Choose the question that brought you here. Open one useful guide, try a small task, and stop when you have what you need.

Take one question further

The same learning habit can travel across subjects, while each subject keeps its own methods. These routes help you notice a difficulty, understand one part of it, and return to something you can do.

A word is familiar, but using it is difficult.

Move from recognising a word to retrieving it in a new context. Understand vocabulary plateaus.

Try it without the guide: Choose one word you already know. Close the guide and use it in a new sentence. Explain why it fits; try another context tomorrow.

A piece of writing has ideas, but the reader loses the thread.

Make the order of events and the links between sentences clear. Explore composition writing.

Try it without the guide: Choose one short paragraph. Read the relevant explanation, close it, and revise the paragraph. Ask someone to tell you what happened and why.

The Mathematics seems familiar, but marks still disappear.

Find the first point where the working stops being reliable. Find Secondary 4 A-Math mark leakage.

Try it without the guide: For a Secondary 4 A-Math question you have attempted, locate the first uncertain line. Repair that step, then try a comparable question without the worked answer.

A Science fact is remembered, but the explanation is incomplete.

Connect the evidence to a scientific idea and the resulting change. Follow the Primary Science learning route.

Try it without the guide: Choose a familiar Primary Science example. Explain the evidence, the idea and the result without notes. Then change one condition and explain your prediction.

Two accounts of the world seem to disagree.

Check the question, source, date and evidence before combining claims. Explore the World Knowledge research library.

Try it without the guide: Take one claim. Find the source best placed to support it, note its date, and state what remains uncertain. Return to your original question.

There is plenty of help, but independence is hard to see.

Check what the learner can understand and do after support is removed. Understand how education works.

Try it without the guide: Choose one small task the child has practised. Agree on a calm, brief attempt without prompts. Use what happens to choose one next step, then stop.

For the structure behind these connections, read the eduKateSingapore runtime manifest and the eduKate ecosystem boot contract. The reader map describes public navigation; those manifests preserve the wider ownership and return rules.

eduKate Asia

Subscribe to
our newsletter

Discover more from eduKate SG

Subscribe now to keep reading and get access to the full archive.

Continue reading